



A G A A T A A A A C A
GACG AGGGAA AAC ACAGTTT AGA ATAAA ACA

GACG AGGGAA AAC ACAGTTT AGA ATAAA ACA

GACG AGGGAA AAC ACAGTTT AGA ATAAA ACA

GACG AGGGAA AAC ACAGTTT AGA TAAAA ACA

PIONEERING PREDICTIVE BIOLOGY



www.cgen.com

PIIONEERING

THE POWER OF PREDICTIVE BIOLOGY

Biology is now in the early stages of evolving from a largely observational science to a predictive science. This evolution is based primarily on a new understanding of life at the molecular level, the ability to generate vast amounts of biological data and ongoing advances in computing power. The goal of predictive biology is to advance the understanding of the underlying mechanisms of life processes, including disease, through a combination of mathematical predictive modeling and experimental validation.

Compugen has focused on establishing predictive biology capabilities since 1995. Utilizing this new and unique research potential, Compugen has demonstrated that basic understandings of life can increase rapidly through the creation of predictive models, experimental validation of the resulting predictions, and continuous feedback and improvement of the models. These understandings continue to fuel Compugen's scientific discoveries and create opportunities for new research applications and products.



MULTIDISCIPLINARY EXPERIENCE

Compugen brings together a research and development team with exceptional multidisciplinary experience and training—the essential starting point for establishing R&D capabilities to advance predictive biology. This unique combination of professionals with prior training in the life sciences, physical sciences, computer sciences and mathematics, has worked together to create and use the knowledge, tools and platforms required for the ongoing transition of biology into a quantitative science.

Compugen's uniquely talented and experienced team has a proven track record of achievements, measured by the Company's growing base of proprietary technologies, innovative tools and platforms that address important challenges faced in pharmaceutical research, and an extensive portfolio of genes and proteins. With this team in place, Compugen is poised to make a significant impact on the continuing evolution of predictive biology—and the ensuing acceleration of the discovery of the therapeutic and diagnostic solutions of the future.

BIOAPPLICATIONS DIVISION

Compugen is pioneering the development and use of computational technologies for the analysis and interpretation of biological data. The Company successfully applies its proprietary core technologies to develop cutting-edge tools, platforms and applications for enhancing drug discovery and development through the prediction, identification and functional analysis of genes, proteins and cell processes. Compugen's BioApplications division is engaged in developing technologies for genomics, functional genomics and proteomics research.

Genomics

LEADS


An advanced computational biology platform for analyzing genomic, expressed and protein data that accelerates the discovery of drug targets and therapeutic markers. Selected clients include: diaDexus, Novartis AG and Warner-Lambert Company, a wholly owned subsidiary of Pfizer Inc.

Gencarta

An annotated database of the genome, transcriptome and proteome that advances post-genomic research. Selected clients include: Avalon Pharmaceuticals, Inc., Kyowa-Hakko Kogyo Co., Ltd. and the Albert Einstein College of Medicine of Yeshiva University.

Bioccelerator

A special-purpose hardware and software package that accelerates homology searches. Selected clients include: Abbott Laboratories, Amgen, Merck Co., Inc. and the United States Patent and Trademark Office.



Functional Genomics

DNA Chip Design

Design based on superior transcriptome modeling containing comprehensive information about all relevant mRNA sequences, taking into account alternative splicing patterns. Selected clients include: Motorola Life Sciences, Novartis AG and Pfizer Inc.

OligoLibraries

Oligonucleotide libraries for high-throughput profiling of gene expression for various organisms, offering increased sensitivity and specificity; co-branded with Sigma Genosys.

Proteomics

Z3 2-D PAGE Analysis

An automatic, high-throughput software for 2-D gel image analysis. Selected clients include: Aventis Pharma, Merck Co., Inc., Procter & Gamble, Pharmacia Corporation and Schering Plough Corporation.

Z4000

A 2-D gel image analysis system that accurately analyzes, manages and controls large-scale proteomic experiments, consisting of hundreds to thousands of gels.

Asp Cys Gln Glu Gly His Ile Leu Lys Met Phe Gly Pro
GAC GAGGGA AAC ACA GTT TAGAAT AAA ACA GA
GAC GAGGGA AAC ACA GTT TAGA
Leu Arg

INNOVATIVE RESEARCH CAPABILITIES

The publication of the first draft of the human genome in February 2001 was a key milestone in life science research. However, for Compugen, the publication had a special significance—it confirmed the Company’s claim, made in 1997, that alternative splicing—resulting in the expression of more than one protein from a single human gene—is the norm rather than the exception. Compugen’s early recognition of this significant phenomenon, obtained through the modeling of alternative splicing, is only one example of the power of predictive biology. This discovery, together with other meaningful biological understandings, is the basis of Compugen’s superior technologies and is incorporated in the Company’s platforms, tools and products. These are applied in-house to discover proprietary genes and proteins, and are also marketed to leading pharmaceutical companies, biotechnology corporations and research institutions across the globe.



INNOVATIVE

Gln G
ACA G
GAC GAC

ro Ser Thr Trp Tyr Val
AC GAGGGA AAC ACA GTT T
AAT AAA ACA GAC GAGGGA
Asn Asp C

NOVEL GENOMICS DIVISION

Compugen’s Novel Genomics division utilizes the Company’s pioneering tools and platforms to discover genes and proteins that can act as biopharmaceuticals, drug targets or diagnostic markers. In addition, the division’s in-house molecular biology laboratory tests and validates discoveries predicted through Compugen’s proprietary computational technologies.

The Company has filed patent applications for thousands of novel transcripts and proteins that may serve as putative drug targets, protein therapeutics or diagnostic markers, primarily in oncology, but also in other areas such as immune-related diseases and central nervous system disorders.

Compugen is investing significant resources in the development and commercialization of candidates for clinical products, and is pursuing partnerships with pharmaceutical and biotechnology companies for further development and commercialization of its intellectual property.

RESEARCH

COMPUGEN IS THE LEADER IN MERGING COMPUTATIONAL TECHNOLOGIES WITH BIOLOGY AND MEDICINE TO ENHANCE DRUG DISCOVERY AND DEVELOPMENT. THE COMPANY'S INNOVATIVE PREDICTIVE BIOLOGY TECHNOLOGIES SUPPORT TWO COMPLEMENTARY PRODUCT DEVELOPMENT AND COMMERCIALIZATION DIVISIONS. COMPUGEN'S BIOAPPLICATIONS DIVISION OFFERS HIGH VALUE PRODUCTS AND SERVICES THAT ENABLE AND ENHANCE THE DISCOVERY AND FUNCTIONAL ANALYSIS OF GENES, PROTEINS AND CELL PROCESSES. COMPUGEN'S NOVEL GENOMICS DIVISION IS DEVELOPING HUMAN THERAPEUTIC AND DIAGNOSTIC PRODUCTS BASED ON TARGET GENES, PROTEINS AND OTHER INTELLECTUAL PROPERTY DISCOVERED THROUGH THE COMPANY'S INNOVATIVE RESEARCH ACTIVITIES.

GAC GAGGGA AAC ACA GTT T

GAC GAGGGA

GAC GATGGA AAC

Ala Arg Asn As

THE COMPUGEN ADVANTAGE

EXPERIENCED,
MULTI-DISCIPLINARY TEAM

INDUSTRY-WIDE COLLABORATIVE
AND COOPERATIVE RELATIONSHIPS

BROAD INTELLECTUAL
PROPERTY POSITION

PROVEN ABILITY TO INTEGRATE
LIFE SCIENCES WITH CUTTING-EDGE
TECHNOLOGIES

SUCCESSFUL TRANSFORMATION
OF CORE TECHNOLOGIES INTO
STATE-OF-THE-ART PRODUCTS

ABOUT COMPUGEN

Compugen was founded in 1993. Its shares have been publicly traded on Nasdaq (NASDAQ:CGEN) since August 2000 and the Tel Aviv Stock Exchange since January 2002. The Company's corporate offices are located in Tel Aviv, Israel, with a wholly owned United States subsidiary headquartered in New Jersey.

SENIOR MANAGEMENT TEAM

Dr. Mor Amitai
Chief Executive Officer and
President

Nurit Benjamini
Chief Financial Officer

Erez Chimovits
Executive Vice President,
Marketing & Sales and President,
BioApplications Division

Martin Gerstel
Chairman of the Board of
Directors

Dr. Salomon Z. Langer
Senior Vice President, Molecular
Biology and Drug Discovery

Lior D. Ma'ayan
Executive Vice President,
Corporate Development



For more information about Compugen Ltd., please contact:

US Headquarters
7 Centre Drive, Suite 7
Jamesburg, NJ 08831, USA
Tel: (609) 655-5105
Fax: (609) 655-5114

West Coast Office
1250 Oakmead Parkway, Suite 210
Sunnyvale, CA 94085, USA
Tel: (408) 730-2678
Fax: (408) 730-6885

Israel Headquarters
72 Pinchas Rosen Street
Tel Aviv, 69512, Israel
Tel: +972-3-765-8585
Fax: +972-3-765-8555

E-mail: info@cgen.com
www.cgen.com
www.labonweb.com